Teva, Samsung Bioepis Extend Biosimilar Alliance in US

Teva has expanded its biosimilars alliance with Samsung Bioepis through a new US licensing and commercialisation agreement covering two FDA-approved immunology biosimilars: ETICOVO (etanercept-ykro), referencing Enbrel, and infliximab-abda, referencing Remicade. Reported on 9 November 2026, the deal extends Teva’s US immunology commercial footprint, supports its broader “Pivot to Growth” strategy and intensifies commercial momentum across the growing US biosimilars market ahead of 2027 market dynamics.

Teva gains US commercialisation rights for ETICOVO when the deal closes, expected by the end of 2026 subject to customary regulatory approvals, and assumes US commercialisation rights for infliximab-abda in Q3 2027. Both biosimilars target chronic inflammatory and autoimmune diseases. Samsung Bioepis retains regulatory oversight and manufacturing for both products, with the arrangement providing Teva commercial pull-through without fixed manufacturing capex. Richard Francis, President and CEO of Teva, framed the agreement around expanding the company’s US immunology portfolio, while Kyung-Ah Kim, President and CEO of Samsung Bioepis, highlighted infliximab-abda’s clinical efficacy and supply track record. Financial terms were not disclosed.

The deal builds on the companies’ established biosimilars partnership, which began with a 2025 US commercialisation agreement for EPYSQLI (eculizumab biosimilar) and a 2026 Canadian commercialisation agreement for OPUVIZ (aflibercept biosimilar), followed by a separate agreement covering up to six early-stage biosimilar candidates. The expanded alliance reinforces Teva’s commercial transformation under the Pivot to Growth strategy, in which biosimilars have become a central pillar alongside innovative medicine growth drivers Austedo and Ajovy. Infliximab and etanercept remain two of the most commercially significant original biologic franchises exposed to biosimilar competition, with US health system procurement increasingly shifting toward lower-cost biosimilar alternatives as payer coverage policies mature. Samsung Bioepis has emerged as one of the most prolific biosimilar developers globally, with a broad immunology, ophthalmology and oncology portfolio supporting its US commercial build.

The commercial signal is a maturing US immunology biosimilars market where strategic commercial-manufacturing partnerships are reshaping competitive economics against legacy originator franchises. Teva’s Pivot to Growth hinges on biosimilars scaling into blockbuster-equivalent commercial anchors. Expect sustained biosimilar deal activity and continued focus on immunology biosimilar commercial pull-through through 2027 and 2028.

For the latest updates and in-depth insights into the world of Pharmaceutical, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!